Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukotriene and thromboxane antagonists

T Obata1, N Yamashita, T Nakagawa

  • 1Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.

Clinical Reviews in Allergy
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survey of perfluorinated compounds (PFCs) in surface waters of Poland.

Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering·2010
Same author

An innovative technique for endoscopic submucosal dissection of early gastric cancer using a new spring device.

Endoscopy·2009
Same author

Discussion on the application of UV/H(2)O(2), O(3) and O(3)/UV processes as technologies for sewage reuse considering the removal of pharmaceuticals and personal care products.

Water science and technology : a journal of the International Association on Water Pollution Research·2009
Same author

A pilot study to assess the efficacy of photodynamic therapy for Japanese patients with actinic keratosis in relation to lesion size and histological severity.

Photodermatology, photoimmunology & photomedicine·2009
Same author

Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy.

Clinical and experimental dermatology·2008
Same author

Total fluorine, extractable organic fluorine, perfluorooctane sulfonate and other related fluorochemicals in liver of Indo-Pacific humpback dolphins (Sousa chinensis) and finless porpoises (Neophocaena phocaenoides) from South China.

Environmental pollution (Barking, Essex : 1987)·2008
Same journal

Immunosuppressive agents and asthma.

Clinical reviews in allergy·1994
Same journal

Novel approaches in immunotherapy.

Clinical reviews in allergy·1994
Same journal

Potassium channel openers and asthma.

Clinical reviews in allergy·1994
Same journal

The legal liability of the Institutional Review Board.

Clinical reviews in allergy·1994
Same journal

New perspectives in information retrieval.

Clinical reviews in allergy·1994
Same journal

Controversy in allergy. Neurologic allergy.

Clinical reviews in allergy·1994
See all related articles

Arachidonate metabolites like leukotrienes and thromboxane are key in asthma. Inhibitors targeting these mediators offer a promising new treatment approach for managing asthma symptoms.

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Pharmacology

Background:

  • Arachidonate metabolites, including leukotrienes and thromboxane, are implicated in bronchial asthma pathogenesis.
  • These mediators exhibit potent bronchoconstrictive and inflammatory activities, exceeding those of histamine and acetylcholine.
  • Elevated levels of these mediators are detected in asthmatic patients post-allergen challenge.

Purpose of the Study:

  • To explore the therapeutic potential of regulating arachidonate metabolite activity in asthma treatment.
  • To review the development and efficacy of novel antiasthmatic agents targeting leukotriene and thromboxane pathways.

Main Methods:

  • Review of preclinical and clinical studies on 5-lipoxygenase inhibitors, leukotriene antagonists, and thromboxane inhibitors/antagonists.

Related Experiment Videos

  • Analysis of the role of thromboxane synthase inhibitor OKY-046 as an antiasthmatic agent.

    • Main Results:

    • Development of various inhibitors and antagonists targeting leukotriene and thromboxane pathways.
    • Demonstrated clinical efficacy of these compounds in managing asthma characteristics.
    • OKY-046, a thromboxane synthase inhibitor, is the first antiasthmatic agent of its kind available in Japan.

    Conclusions:

    • Targeting arachidonate metabolites represents a novel therapeutic strategy for bronchial asthma.
    • Inhibitors and antagonists show potential in mitigating airway obstruction, inflammation, and hyperresponsiveness.
    • Further clinical studies on new leukotriene and thromboxane antagonists are anticipated.